SWIXX BIOPHARMA AND LILLY STRATEGIC COLLABORATION ACROSS EIGHT MARKETS IN CENTRAL AND EASTERN EUROPE

- ***Swixx takes on promotion and distribution of select products within Lilly's portfolio across obesity, diabetes, hematology/oncology and immunology***
- ***Strategic collaboration spans eight markets of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, Moldova, North Macedonia, Serbia and Ukraine***

Baar, Switzerland, October 1, 2026 – Swixx BioPharma AG, a global commercial platform dedicated to unlocking access to innovative medicines worldwide, is pleased to announce the signature of a new Distribution and Promotion Agreement ("Agreement") with Eli Lilly Export S.A. ("Lilly"). Under the new Agreement, Swixx is appointed to promote and distribute select products within Lilly's portfolio in Albania, Bosnia and Herzegovina, Kosovo, Montenegro, Moldova, North Macedonia, Serbia and Ukraine. The Agreement includes select products within Lilly's portfolio across several therapeutic areas in obesity, diabetes, hematology/oncology and immunology.

The strategic collaboration brings together select products within Lilly's portfolio with Swixx's established local presence and operational capabilities, further strengthening Swixx's role as a trusted partner to multinational and biotech companies seeking an indirect operating model to ensure access to their innovative medicines.

"**Dr. Dezso Martha, COO** of Swixx's European markets, commented: "This Agreement is another important step in Swixx's mission to help ensure that innovative medicines reach patients in markets across CEE where strong local execution is essential. Lilly's trust in Swixx reflects the depth of our capabilities across these countries, including our experience in representing strategic collaboration portfolios in chronic diseases, such as obesity. We see this as an area of significant and continuing healthcare need, and we remain committed to addressing it together with our partner and healthcare stakeholders."

"**Predrag Lukić, General Manager Non-EU countries**, added: "Across all countries included in this strategic collaboration, Swixx/Amicus has full-scale organizations in place. Our teams are ready to support access to Lilly's innovative medicines with strong local capabilities and proximity to healthcare stakeholders, continuing the legacy built by Lilly. The inclusion of obesity therapy is especially meaningful given the growing burden of obesity, a complex chronic disease affecting millions of people worldwide. We will be working closely with Lilly and all stakeholders to support continued access to their medicines."

"**Elias Khalil, President and General Manager, Italy Hub:** "At Lilly, we believe that every patient who can benefit from our innovations should have the opportunity to access them. This strategic collaboration with Swixx BioPharma strengthens our ability to expand access to Lilly's medicines and reach more patients across these eight markets. By combining Lilly's innovative portfolio with Swixx's established commercial reach and regional expertise, we can bring our medicines to more patients while maintaining a strong commitment to those who already rely on our therapies."

About Swixx Group

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With presence in >50 countries, more than 2,100 employees and sales which exceeded 1.4 billion Euros in 2025, the Group is one of the fastest-growing independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and CNS therapy area talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.

Swixx Group investor and partner inquiries:

Jean-Michel Lespinasse, CEO
bd.info@swixxbiopharma.com

Stuart Swanson, Head of Corporate Development
bd.info@swixxbiopharma.com

Swixx Group media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086